SHL Medical AG

10/07/2026 | Press release | Distributed by Public on 10/07/2026 04:14

SHL Medical wins Partnership Innovation Award at PDA Universe 2026

PDA Universe 2026 brought two recognitions for SHL Medical research.

SHL Medical left PDA Universe 2026 with more than a new autoinjector to show.

A study presented by SHL Medical's Alex Lyness, PhD and John Burke of Team Consulting won the conference's Partnership Innovation Award, recognizing their work on how large-volume subcutaneous injections can be studied once the injected fluid moves beyond the device and into tissue.

Their presentation, "Investigating Imaging Modalities to Characterize Injection Deposition for Large-Volume Subcutaneous Device Design," compared different approaches to observing and characterizing injection deposition, part of a broader effort to close some of the evidence gaps that still surround large-volume subcutaneous delivery. The work explored a fit-for-purpose methodology for understanding how injected volume disperses beneath the skin.

Alex Lyness of SHL Medical and John Burke of Team Consulting received the Partnership Innovation Award at PDA Universe 2026 for their research into large-volume subcutaneous injection deposition.

The recognition came during a particularly active PDA Universe for SHL Medical. The conference also marked the debut of Magnitude, our cartridge-based large-volume autoinjector, alongside a wider program of research and technical discussion around injection performance, usability, and device development.

Patient-centered autoinjector activation earns further recognition

The award was not SHL Medical's only recognition at the event. Nenad Suknovic, PhD, was named a finalist for the Innovation Award for "Finding the Sweet Spot: A Patient-Centered Approach to Optimizing Activation Force in Subcutaneous Autoinjectors for Patients with Obesity."

Nenad Suknovic of SHL Medical presents research on real-world autoinjector activation and patient-centered activation force at PDA Universe 2026.

Suknovic's study approached drug delivery from the other end of the injection experience: the moment a patient activates the device. It examined how activation force interacts with patient characteristics, including skin stiffness, to better understand what patient-centered autoinjector activation should look like.

The two studies reflect how SHL Medical contributes beyond device engineering alone, building evidence around how devices should perform, how patients interact with them, and what happens after an injection is delivered.

That contribution to the wider industry conversation extends beyond Palm Springs. During the same period, SHL Medical experts contributed to industry discussions at CPHI Milan, while further research will be presented at PODD®in Boston later this month.

What this research means for pharma drug delivery programs

For pharma and biotech companies considering self-injection for an existing or emerging drug program, those discussions ultimately come back to practical development questions: how a formulation behaves through the delivery system, how much can be delivered subcutaneously, how patients interact with the device, and which device architecture best fits the drug program.

Those are also the questions SHL Medical works alongside pharma partners to answer as combination product programs move from formulation to device strategy and toward the patient.

SHL Medical AG published this content on October 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 07, 2026 at 10:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]